Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach
Status: Recruiting
Location: See all (5) locations...
Intervention Type: Diagnostic test, Device, Procedure
Study Type: Observational
SUMMARY
The study is aimed to determine the potential of volatile marker testing for gastric cancer screening. The study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:
• Patients with verified gastric cancer (Group 1 \& 2)
• Patients undergoing or having undergone upper endoscopy according to clinical indications (Group 3 \& 5)
• Average-risk population group aged 40-64 at inclusion without alarm symptoms (Group 4)
• Motivation to participate in the study
• Physical status allowing volatile marker sampling and other procedures within the protocol
• Signed consent
Locations
Other Locations
Brazil
A.C.Camargo Cancer Center
RECRUITING
São Paulo
Chile
Pontificia Universidad Catolica de Chile
NOT_YET_RECRUITING
Santiago
Colombia
Centro Javeriano de Oncología, San Ignacio University Hospital
NOT_YET_RECRUITING
Bogotá
Latvia
Institute of Clinical and Preventive Medicine, University of Latvia
RECRUITING
Riga
Ukraine
National Cancer Institute of Ukraine
RECRUITING
Kiev
Contact Information
Primary
Marcis Leja, MD, PhD
marcis.leja@lu.lv
+37129497500
Backup
Daiga Santare, MD, PhD
daiga.santare@lu.lv
+37129221107
Time Frame
Start Date: 2019-11-01
Estimated Completion Date: 2026-12
Participants
Target number of participants: 5000
Treatments
Gastric cancer patients undergoing surgery
Patients with histologically confirmed gastric cancer (adenocarcinoma) planned for surgical management
Gastric cancer patients
Patients with histologically confirmed gastric cancer (adenocarcinoma)
Control group patients without gastric cancer
Patients without gastric malignant disease according to data obtained in upper endoscopy
Average risk population
Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer
Patients with dyspeptic symptoms
Patients with dyspeptic symptoms or other complains being referred for upper endoscopy (Chile)
Related Therapeutic Areas
Sponsors
Collaborators: JLM Innovation GmbH, Universitaet Innsbruck, Universidad de Pamplona, VTT Technical Research Centre of Finland, Technion, Israel Institute of Technology, University of Ulm, Uppsala University, Pontificia Universidad Catolica de Chile, Hospital Universitario San Ignacio, National Cancer Institute of Ukraine, AC Camargo Cancer Center
Leads: University of Latvia